PNH is a rare and debilitating hematologic disorder affecting an estimated 10,000-15,000 people in the U.S. Patients diagnosed with PNH are challenged by symptoms of anemia, fatigue, and blood clots.

Reports $709 million in preliminary1 full-year 2024 U.S. net product revenues$611 million in SYFOVRE® U.S. net product revenues, including $167 ...

The question is whether the added convenience offered by crovalimab will be enough to carve out a niche for the drug in the increasingly crowded PNH market. AZ is working hard to build a market ...

Other competitors have entered the increasingly crowded looking PNH market, however, including Apellis Pharma/Sobi's complement C3 inhibitor Empaveli/Aspaveli (pegcetacoplan), which was approved ...

Ilene Weitz, MD, details a few abstracts on paroxysmal nocturnal hemoglobinuria (PNH) treatments that will be presented at ASH 2024, particularly data on danicopan as an add-on to ravulizumab or ...

Apellis' pegcetacoplan, approved for GA and PNH, faces challenges with safety concerns and EU rejection, but shows promise in IC-MPGN and C3G trials. Financially, Apellis has a market cap of $4 ...